Related Experiment Videos
Diagnosis and management of iron-induced heart disease in Cooley's anemia
1Heart Failure/Transplant Center, Allegheny University Hospitals, Philadelphia, Pennsylvania 19129, USA. jessup@AUHS.edu
Insights
Patients with beta-thalassemia face cardiac risks from iron overload. Early intervention and monitoring are crucial to prevent heart failure and manage iron-induced heart disease in these patients.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Homozygous beta-thalassemia patients require chronic transfusions, leading to iron overload.
- Iron deposition causes cardiac pathology, including fibrosis, hypertrophy, and myopericarditis, even with optimal chelation.
- Poorly chelated patients are at high risk for fatal heart failure.
Purpose of the Study:
- To highlight the cardiac risks in beta-thalassemia patients.
- To suggest exploring interventions for iron-induced heart disease.
- To emphasize the need for quantitating long-term cardiac effects.
Main Methods:
- Review of existing data on cardiac dysfunction in beta-thalassemia.
- Observation of cardiac pathology in both optimally and poorly chelated patients.
- Consideration of ACE inhibitors' success in other cardiomyopathies.
Main Results:
- Cardiac dysfunction, primarily diastolic abnormalities, occurs even in optimally chelated patients.
- Severe, fatal heart failure is predictable in poorly chelated individuals.
- Long-term risks like ischemic cardiac disease may compound existing cardiac dysfunction.
Conclusions:
- Multicenter trials are suggested to explore methods for stabilizing cardiac function.
- Further research is needed to quantify long-term adverse effects of iron deposition.
- Proactive management is essential to mitigate cardiac complications in beta-thalassemia.
Abstract:
Patients with homozygous beta-thalassemia are chronically transfused and, if not assiduously chelated, are at risk for cardiac dysfunction. Available data suggest that even in optimally chelated patients, cardiac pathology is abnormal secondary to iron deposition, fibrosis, hypertrophy, and the structural effects of chronic anemia. Evidence of myopericarditis may also be found. Cardiac performance is usually only subtly affected, primarily with diastolic abnormalities not routinely detected on echocardiograms or nuclear scan. In poorly chelated patients, severe heart failure occurs and is easily predictable but invariably fatal, despite treatment with diuretics, vasodilators, inotropes, and antiarrhythmics. Based on successful prevention of heart failure with ACE inhibitors in other forms of cardiomyopathy, we suggest multicenter trials to explore methods to stabilize cardiac function in patients at risk for iron-induced heart disease. Long-term adverse effects of iron deposition, diastolic dysfunction, and abnormal hormone regulation need to be quantitated in patients reaching their third and fourth decades when the potential for ischemic cardiac disease could compound cardiac dysfunction.